Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics


Deciphera Pharmaceuticals, Inc. (DCPH)

Today's Latest Price: $58.16 USD

1.56 (-2.61%)

Updated Jul 1 6:55pm

Add DCPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

DCPH Stock Summary

  • Deciphera Pharmaceuticals Inc's stock had its IPO on September 28, 2017, making it an older stock than merely 8.9% of US equities in our set.
  • DCPH's price/sales ratio is 133.11; that's higher than the P/S ratio of 97.82% of US stocks.
  • With a year-over-year growth in debt of 780.78%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 97.7% of about US stocks.
  • Stocks that are quantitatively similar to DCPH, based on their financial statements, market capitalization, and price volatility, are BBIO, EIDX, RCUS, SGMO, and EPZM.
  • Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Daily Price Range
DCPH 52-Week Price Range

DCPH Stock Price Chart Technical Analysis Charts


DCPH Price/Volume Stats

Current price $58.16 52-week high $71.11
Prev. close $59.72 52-week low $19.88
Day low $57.57 Volume 521,200
Day high $60.73 Avg. volume 587,426
50-day MA $56.43 Dividend yield N/A
200-day MA $51.31 Market Cap 3.25B

Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio


Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.


DCPH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DCPH Latest Social Stream


Loading social stream, please wait...

View Full DCPH Social Stream

Latest DCPH News From Around the Web

Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

Deciphera's ripretinib OK'd in Canada for 4th-line GIST

Health Canada has approved Deciphera Pharmaceuticals' (DCPH) Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor ((GIST)) in patients who have received prior treatment with imatinib (Novartis' Gleevec), sunitinib (Pfizer's Sutent) and regorafenib (Bayer's Stivarga)....

Seeking Alpha | June 22, 2020

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib. The QINLOCK New Drug Submission was approved by Health Canada under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners. In May 2020, QINLOCK was approved by the U.S. FDA for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more ...

Yahoo | June 22, 2020

3 “Strong Buy” Healthcare Stocks That Should Remain Healthy

For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of COVID-19. This week, however, U.S. stocks recovered some lost ground thanks to strong retail sales data. There's a lot going on in the markets, and the only certainty is uncertainty.Against this backdrop, we turned our attention to defensive stocks in the healthcare sector. In general, these stocks provide stable earnings regardless of the stock market’s state due to the constant demand for their products or services.With this in mind, we used TipRanks’ database to identify three defensive healthcare stocks with upside potential north of 20%. Not to mention each of these companies has ...

Yahoo | June 17, 2020

Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET. The conference will be held in a virtual meeting format.

Yahoo | June 11, 2020

Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST). The INVICTUS study met its primary endpoint, demonstrating a statistically significantly improvement in progression free survival (PFS) in patients randomized to QINLOCK compared with patients receiving placebo. The safety profile observed in INVICTUS was consistent with previously published results, and results from the study were previously presented at the European Society of Medical Oncology Congress in September 2019.

Yahoo | June 8, 2020

Read More 'DCPH' Stories Here

DCPH Price Returns

1-mo -1.96%
3-mo 56.98%
6-mo 1.64%
1-year 150.80%
3-year N/A
5-year N/A
YTD -6.56%
2019 196.52%
2018 -7.41%
2017 N/A
2016 N/A
2015 N/A

Continue Researching DCPH

Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:

Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9541 seconds.